Friday, November 2, 2012

HLF -5.1%

Herbalife Ltd. (HLF) dropped 5.1% on November 2, 2012 (S&P - 0.9%). Although no company-specific event contributed to the decline, investors may have interpreted Monday's +3% earnings surprise as a sign of weakness - HLF has beat the mean consensus EPS estimate by 14.3% on average over the previous 4 quarters. Despite this dip, we continue to believe that the growth of daily consumption distribution and will drive net sales, and infrastructure investment associated with the company's 'Seed to Feed' initiative will grow margins moving forward.

MET Q3 earnings


MetLife inc. (MET) released quarter three earnings on October 31st.

A loss of $984 million including $1.6 billion in goodwill impairment related to its retail annuity business as MET reduces its exposure to the risky product. CEO Steven Kandarian is targeting back offerings such as variable annuities by 12% by 2016. Variable annuity sales fell 46% year over year in a reflection of this plan moving forward.

Operating profit climbed to $1.32 a share from $0.91 just a year earlier beating street estimates by $0.04. Asian operating earnings rose 17% to 259 million while the America’s grew by 58% to $1.2 Billion.

Management gave no guidance on possible losses incurred by Hurricane Sandy. The market has responded negatively to the stock as they try to price in possible exposure to the storm.

MET continues to progress in its sale of MetLife to GE Capital. This quarter changes were made to the deal to shift regulatory oversight of the deal away from the FDIC. The sale is projected to be approved prior to a January deadline where MET would have to submit a new capital plan to the Federal Reserve. The sale of MetLife Bank is the largest short term driver for the stock as it would allow MetLife Inc. to raise the annual dividend and start share repurchasing programs. 

Thursday, November 1, 2012

HLF Q3

Herbalife Ltd. (HLF) released Q3 2012 results on Monday, October 29.

Net Sales of $1.0 billion (+14%) were driven by a 17% increase in volume points over the prior year period. A 100 bps decrease in EBIT margin (15.3%) during the quarter was due to FX headwinds. Net Income totalled $117.8 - a 9% increase over Q3 2011.

Q3 EPS of $1.04 beat the consensus estimate by $0.03 or 3%. EPS guidance for FY 2012 has been raised from $3.88 - $3.98 to $3.99 - 4.03. Management has also introduced full-year 2013 guidance of $4.40 - $4.55.

Regarding our thesis, the expansion of the daily consumption DMO among distributors has continued into Q3. HLF now estimates the number of nutrition clubs worldwide to be 43,000, representing an increase of 18% versus Q2. Daily consumption distribution methods now account for approximately 40% of total sales volume (vs. 37.5% in Q2). Additionally, the company continues to invest in infrastructure to support global growth. During Q3, HLF's board approved the construction of a $130 million East Coast (U.S.) manufacturing facility that management anticipates will be complete and operational in 2014.

Shares opened +4.6% when trading resumed Wednesday (October 31) morning.

Watson Pharmaceuticals (WPI) Q3 Earnings release


Watson Pharmaceuticals released its third quarter earnings this morning. This will be their last stand alone quarter before their Actavis acquisition will begin to shape their financial statements.

Net Revenue increased to $1.29 Billion based on several new Generic and Branded product debuts resulting in an increase of 19% versus prior year $1.08 Billion. By segment, Global Generics grew by 14% to $920.9 M, an increase of 118.4 M but $300 M shy of street estimates. Global Brands increased to ~10% to $121.3 M and Global Distribution increased significantly by 44% to $243 M versus last year’s $168.8 M. This increase was attributable to new third-party product launches during the third quarter

Total Operating expenses increased 27% to $1,196 B due to Increased marketing expenses from growing international sales, third-party costs in biosimilars, and other costs related to the Actavis Acquisition

Adjusted EBITDA saw a significant increase of 18% to $304.6 M versus 3Q 2011’s $258.2 M

Adjusted Net income showed a significant increase of 24.2% to $172.3 M. This resulted in $1.35 per diluted share on a non-gaap basis versus last year’s $1.09. This landed within the mid to upper end of analyst expectations.

Looking ahead, WPI estimates total net revenue for 2012 to be $5.9 Billion with adjusted non-gaap earnings between $5.85 and $5.95 per diluted share. Adjusted EBITDA should fall between $1.36 and $1.39 Billion

2013 non-GAAP EPS is expected to grow between 30% and 40% over the high end of the combined range of 2012. This is inclusive of an additional 5.5 Million shares outstanding at the close of the Actavis acquisition



Wednesday, October 31, 2012

DaVita Inc. 3Q12 earnings

-->
Yesterday, October 30th, DaVita released its earnings for the 3Q12.  The company posted solid third quarter results with earning per share of $1.52.  Net income jumped 6.9 percent, from $135.4 million, or $1.42 per share, in the third quarter of 2011 to $144.7 million, or $1.50 a share, during the same time period this year.  The company reported an additional $5.4 million after-tax-debt expense, or $0.06 per share, resulting from the potential acquisition of HCP. Operating income for the three and nine months ended September 30, 2012—including related expenses of $78 million—was $909 million, which is up from $801 million in 2011.  U.S. treatments for the third quarter were 5,550,645 or 71,162 treatments per day, an increase of 12.3 percent over the third quarter of 2011.
            Kent J. Thiry, Chairman and Chief Executive Officer, stated in the third quarter earnings call, that he expected the previously announced acquisition of HealthCare Partners (HCP) to close soon.  Once the acquisition is completed and HCP is fully integrated, DaVita’s leverage ratio will be 3.7 times net-debt to EBITDA, which is only marginally above their long-stated preferred leverage range of 3.0 to 3.5.  Therefore, they believe that this acquisition represents a “tremendous upside” to shareholder platform without significant changes to the company’s balance sheet.  The company has also altered its credit limits and facility agreements to allow an additional borrowing of $3 billion to be used to finance parts of the HCP transaction.
            In terms of outlook for 2013, Thiry stated that there are, “ significant number of headwinds and challenges to face on both sides of our enterprise”. More specifically, management is concerned with a potential 2 percent cut to the Medicare reimbursement, which could directly affect the revenues from their dialysis business.  In addition, they believe there is some uncertainty around their commercial book of business, as DaVita continues to lose money on Medicare treatments and has been relying on private insurance to make up for the loss.  On a positive note, Thiry believes that DaVita’s core kidney care business remains strong and is continuing to make improvements in clinical care—allowing the company to retain a strong market position, steady volume growth and strong stable cash generation.
            In terms of guidance for 2013 DaVita updated their operating income to a range of $1.315 billion to $1.33 billion, not including expenses related to the question of HCP.  In the reminder of 2012, management expects HPC to contribute $25 million to $30 million per month in operating income once the merger is completed.  In addition, 2013 operating cash flow guidance of $1.35 billion to $1.5 billion.

Saturday, October 27, 2012

Apple Sell Thesis (1/2 Position)


Before the iPhone 5 announcement, we cut our AAPL position in half (approximately $670) to take profits and eliminate the risk of underperformance after the iPhone release. This is precisely what happened and on October 12th (price $630), we reevaluated the situation and decided to double down on the position ahead of the iPad mini announcement and Q4F2012 earnings. Unfortunately, a number of factors caused the stock price to decline 4% (our stop loss for this particular trade), including iPad mini margin concerns and general fears about the upcoming earnings announcement. Management seemed to drive a point home throughout the conference call: results could be rocky in the short term, but the company is well positioned to take advantage in the long term as costs decline and production inefficiencies abate (see earnings release). Therefore, at this point we are withdrawing from the ST trade at the stop-loss point that was created at the inception of the trade ($605). Our LT AAPL thesis remains in tact, leaving us with a normal weighting position going forward.  

-Joe Esposito 

Apple 4QF2012 Conference Call (Thursday 5PM)


Peter Oppenheimer, CFO
            Apple released its fourth quarter fiscal 2012 earnings today AMC. About a half hour before trading, a Bloomberg headline indicated that AAPL would be launching its own Internet radio business in 2013. Pandora’s shares gapped down 20%, at which point trading was halted.
            AAPL released earnings of $8.67 (increase of 24% y/y) compared to expectations of $8.75 and with revenue of $36 billion versus expected revenue at $35.80 billion (Reuters). International revenue contributed to 60% of total revenue for the quarter. Revenue increased 27% y/y while operating margin represented 30.4% of revenue.  The company showed strength in its computer segment, with a 1% y/y growth compared to an industry expected 8% contraction for the quarter. Portable computers not make up 80% of the computer sales mix at AAPL. Strong demand contributed to a lower than expected Mac channel inventory at the end of the quarter (3-4 weeks compared to target 4-5 weeks).
            iPods market share of MP3 players was 70% in September according to independent research by MPD. A new version of iTunes will be launched soon to integrate iCloud while bringing a cleaner interface to the mobile and computer market.  iPhone sales increased 58% y/y compared to industry expectations of 45%. The iPhone 5 has been launched in 31 countries and is targeted to reach 100 before the end of the year. iPhone 5 demand continues to outstrip supply. AAPL recognizes revenue for iPhone products when it delivers the product to the customer, so this backlog will not be recognized until next quarter. Revenue for iPhone accessories increased 51% y/y, driven by new headphones, iPhone 5 cases and an effective marketing campaign. 
            Oppenheimer gave strong comments on corporate sales and iPhone integration into businesses. For example, BBC, WSJ and other media juggernauts have given iPhones to reporters on the ground to take HD video and pictures, which have been used in newspapers, websites and Twitter blogs. Also, companies like Amtrak have utilized the iPhone to save on paper costs. He remains very bullish on iPhone and iPad corporate sales in the face of increased competition going forward. iPad sales increased 26% y/y (less than anticipated). AAPL’s software developers have been working around the clock to fix the Maps App problems.
            New store openings across the globe have been extremely successful, notably a second store opening in Hong Kong. On average, AAPL stores receive 19,000 visitors per week per store.

Outlook
            Revenue expected to be $52 billion in the December quarter. Gross margin is expected to be 36%, tax rate of 26% and $11.75 EPS expectations. Expecting a 73% y/y growth in iPhones and 80% growth in iPads. Future revenue will continue to benefit form a strong pipeline and movement down the cost curve as production becomes more efficient.

Question/Commentary Notes
            Y/y expected decline in EPS in December attributed to 14th week last year’s quarter, stronger USD, and lower gross margin. All new products currently have higher costs (lower gross margins)—they are high on the cost curve. This has been the case with products in the past. iPad mini margin will be below corporate product average, due to the nature of the product. AAPL has never introduced so many products at the same time, which is why you will see higher costs in the ST. Lower iPhone 4/4s price will contribute to y/y decline as well.
            In significant state of iPhone 5 backlog right now. Output improved significantly since earlier in the month. This is the largest volume ramp in AAPL history for any product.
            Confident that tablet market will surpass PC market. Enormous opportunity for AAPL in this area, extremely excited for Friday when the mini’s go on sale.
            China: Q4 revenue up 27%, mac up 44%, iPad up 45% (Greater China). FY revenue up 78% in China, which is now 58% of AAPL.
            “I haven’t played with the Surface yet, but we are reading that it’s a fairly compromised and confusing product.” –Tim Cook
           
-Joe Esposito